Berberine in Non-Alcoholic Fatty Liver Disease—A Review

Koperska, Anna; Wesołek, Agnieszka; Moszak, Małgorzata; Szulińska, Monika

doi:10.3390/nu14173459

Cited by 25 publications

(11 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Glycyrrhetinic acid, another active ingredient of licorice, can also improve the damaged autophagy flux and reduce the excessive production of inflammatory cytokines such as TNF-α, IL-6 and IL-1β by regulating the STAT3-HIF-1 pathway of macrophages ( 200 ). Curcumin and berberine, two of the most studied natural products for the treatment of NAFLD, have shown positive results in several clinical trials ( 201 , 202 ). Mechanistic studies have also demonstrated the effect of both on macrophage polarization ( 203 , 204 ).…”

Section: Potential Drugs Targeting Pcd Of Macrophagesmentioning

confidence: 99%

Programmed cell death and lipid metabolism of macrophages in NAFLD

et al. 2023

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) has now become the leading chronic liver disease worldwide with lifestyle changes. This may lead to NAFLD becoming the leading cause of end-stage liver disease in the future. To date, there are still no effective therapeutic drugs for NAFLD. An in-depth exploration of the pathogenesis of NAFLD can help to provide a basis for new therapeutic agents or strategies. As the most important immune cells of the liver, macrophages play an important role in the occurrence and development of liver inflammation and are expected to become effective targets for NAFLD treatment. Programmed cell death (PCD) of macrophages plays a regulatory role in phenotypic transformation, and there is also a certain connection between different types of PCD. However, how PCD regulates macrophage polarization has still not been systematically elucidated. Based on the role of lipid metabolic reprogramming in macrophage polarization, PCD may alter the phenotype by regulating lipid metabolism. We reviewed the effects of macrophages on inflammation in NAFLD and changes in their lipid metabolism, as well as the relationship between different types of PCD and lipid metabolism in macrophages. Furthermore, interactions between different types of PCD and potential therapeutic agents targeting of macrophages PCD are also explored.

show abstract

Section: Potential Drugs Targeting Pcd Of Macrophagesmentioning

confidence: 99%

Programmed cell death and lipid metabolism of macrophages in NAFLD

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Berberine can directly or indirectly target multiple pathways involved in the brotic reactions in HSCs 24 . Therefore, it has received considerable attention in the treatment of MASH 25 . Herein, we used different concentrations of TJ-15 to observe its effects on LX2 cells.…”

Section: Discussionmentioning

confidence: 99%

The Kampo formulae “Juzen-taiho-to (TJ-48), Boi-ogi-to (TJ-20), Keishi-bukuryo-gan (TJ-25),and Oren-gedoku-to (TJ-15)” inhibit the activation of hepatic stellate cells

Jiang,

Li,

Ngo

et al. 2024

Preprint

View full text Add to dashboard Cite

Aim This study aimed to explore the effects of TJ-48 (juzen-taiho-to), TJ-20 (boi-ogi-to), TJ-25 (keishi-bukuryo-gan), and TJ-15 (oren-gedoku-to) on hepatic stellate cell (HSC) activation, as well as the impact of different concentrations of Kampo formulae on metabolic dysfunction-associated steatohepatitis (MASH) liver fibrosis by analyzing the changes in the expression levels of alpha smooth muscle actin (α-SMA) and collagen type I alpha 1 chain (COL1A1) gene. Methods Different concentrations (0, 100, 500, 1000 µg/mL) of Kampo formulae were added to HSC-LX2 cells and cultured for 48 h. Real-time PCR and western blotting were used to detect α-SMA and COL1A1 mRNA and protein expression. Results Increasing TJ-48 concentrations caused the α-SMA and COL1A1 mRNA and protein expression to decrease sequentially, with a significant decrease in α-SMA mRNA levels at 500 and 1000 µg/mL TJ-48. Further, increasing TJ-20 concentrations resulted in a linear decrease in α-SMA mRNA expression. Similarly, adding TJ-25 led to a sequential decrease in α-SMA and COL1A1 mRNA and protein expression, with a significant drop in α-SMA mRNA and protein expression at 500 and 1000 µg/mL TJ-25. Likewise, the addition of TJ-15 caused a steady decline in α-SMA mRNA and protein levels, with a significant decrease in α-SMA mRNA and COL1A1 mRNA and protein levels at 1000 µg/mL TJ-15. Conclusion Our findings indicated that TJ-48, TJ-20, TJ-25, and TJ-15 significantly inhibited the activation of hepatic stellate cells and prevented the development of liver fibrosis. Future in vivo and clinical studies are warranted on this topic.

show abstract

“…Preclinical and clinical studies show that berberine has glucose-and lipid-lowering effects, which may be beneficial for patients with NAFLD/NASH. 76 In an RCT involving 184 patients with NAFLD, treatment with berberine plus lifestyle intervention reduced LFC more significantly than lifestyle intervention alone. This was accompanied by better improvement in body weight, homeostasis model assessment of insulin resistance (HOMA-IR) index, and serum lipid profile.…”

Section: A Phase II Trial Investigating the Efficacy And Safety Of Ch...mentioning

confidence: 99%

“…Berberine, an active single compound extracted from the Chinese herb Coptis chinensis , is widely used in China to treat diarrhoea. Preclinical and clinical studies show that berberine has glucose‐ and lipid‐lowering effects, which may be beneficial for patients with NAFLD/NASH 76 . In an RCT involving 184 patients with NAFLD, treatment with berberine plus lifestyle intervention reduced LFC more significantly than lifestyle intervention alone.…”

Section: Advances In Nafld/nash Treatment Regimens In Chinamentioning

confidence: 99%

Epidemiological characteristics and management of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis in China: A narrative review

Liu

Hong

2023

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

Aim With industrialization and spread of the westernized lifestyle, the number of people affected by non‐alcoholic fatty liver disease (NAFLD)/non‐alcoholic steatohepatitis (NASH) is growing rapidly in China; this has become a major public health concern. To better understand the burden and characteristics of NAFLD/NASH in China, we aim to perform a narrative review of the literature published in this field. Materials and Methods We carried out a comprehensive electronic search of five English‐language and three Chinese‐language databases, to identify studies regarding NAFLD or NASH published from inception to November 30, 2022. Epidemiological studies of NAFLD/NASH in China were particularly noticed and summarized. We also searched the http://www.clinicaltrials.gov and http://www.chictr.org.cn websites for the registered trials on the treatment of the disease led by Chinese investigators or located in China. Results The increasing rate of NAFLD prevalence in China is strikingly high, reaching more than twice that in western countries. The prevalence of NAFLD is nearly 30% of the general Chinese population, making it the leading cause of chronic liver diseases. The prevalence of NAFLD/NASH varies between provinces/regions, age groups, sexes, and individuals with different metabolic profiles. NAFLD co‐exists in many Chinese patients with chronic hepatitis B. Since 2020, more Chinese studies have used the term metabolic‐associated fatty liver disease (MAFLD), emphasizing the underlying metabolic disorders that occur concurrently with this disease. Several clinical trials involving lifestyle interventions, antidiabetic drugs, or traditional Chinese medicines, registered by Chinese investigators, have been completed or are ongoing. Moreover, several innovative targeted therapies developed in China are revolutionizing the treatment of NAFLD/NASH. Conclusions NAFLD has cast a heavy burden on the Chinese healthcare system. Chinese scholars are making efforts to achieve the optimal management of this disease.

show abstract

Berberine in Non-Alcoholic Fatty Liver Disease—A Review

Cited by 25 publications

References 59 publications

Programmed cell death and lipid metabolism of macrophages in NAFLD

Programmed cell death and lipid metabolism of macrophages in NAFLD

The Kampo formulae “Juzen-taiho-to (TJ-48), Boi-ogi-to (TJ-20), Keishi-bukuryo-gan (TJ-25),and Oren-gedoku-to (TJ-15)” inhibit the activation of hepatic stellate cells

Epidemiological characteristics and management of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis in China: A narrative review

Contact Info

Product

Resources

About